-
1.发明申请Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease 审中-公开包括用于治疗系统性疾病和疾病的TGF-β超家族成员的蛋白质的外周管理公开(公告)号：US20120258917A1
公开(公告)日：2012-10-11
申请号：US13444282
申请日：2012-04-11
IPC分类号： A61K38/18 , C07K14/475 , A61P19/08 , A61P19/02 , A61P35/00 , A61P19/04 , A61P1/16 , A61P25/16 , A61P9/10 , C07K14/51 , A61P19/10
CPC分类号： A61M5/00 , A61K9/0019 , A61K38/1841 , A61K38/1875
摘要： The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily via a peripheral mode of administration. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the peripheral site of intravenous administration of the bioactive agent.
摘要翻译： 本发明涉及用于完成微生物活性剂的系统递送的方法和组合物，所述生物活性剂例如但不限于TGF-和bgr的蛋白质; 超家族通过外部管理模式。 根据本发明，示例性生物活性剂是BMP-7。 本发明进一步提供骨骼疾病例如骨质疏松症的微创全身治疗以及受损或患病的非矿化组织和器官等肾脏的微创全身治疗。 本发明的实践消除了静脉内施用生物活性剂的周边部位的不良副作用。
-
2.发明申请Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease 审中-公开包括用于治疗系统性疾病和疾病的TGF-β超家族成员的蛋白质的外周管理公开(公告)号：US20100204123A1
公开(公告)日：2010-08-12
申请号：US12705259
申请日：2010-02-12
IPC分类号： A61K38/18 , A61P19/02 , A61P19/08 , A61P19/10 , A61P19/04 , A61P25/16 , A61P13/12 , A61P9/10 , A61P3/04 , A61P3/10 , A61P1/16 , A61M25/00 , A61M5/00 , A61B17/34
CPC分类号： A61M5/00 , A61K9/0019 , A61K38/1841 , A61K38/1875
摘要： The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily via a peripheral mode of administration. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the peripheral site of intravenous administration of the bioactive agent.
摘要翻译： 本发明涉及用于完成微生物活性剂的系统递送的方法和组合物，所述生物活性剂例如但不限于TGF-和bgr的蛋白质; 超家族通过外部管理模式。 根据本发明，示例性生物活性剂是BMP-7。 本发明进一步提供骨骼疾病例如骨质疏松症的微创全身治疗以及受损或患病的非矿化组织和器官等肾脏的微创全身治疗。 本发明的实践消除了静脉内施用生物活性剂的周边部位的不良副作用。
-
3.发明申请Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members 审中-公开包含TGF-β超家族成员的蛋白质微创系统递送的组成和方法公开(公告)号：US20100204124A1
公开(公告)日：2010-08-12
申请号：US12705367
申请日：2010-02-12
IPC分类号： A61K38/19 , A61P19/02 , A61P19/04 , A61P1/16 , A61P13/12 , A61P9/10 , A61P25/16 , A61P27/02 , A61P3/10 , A61P3/04 , A61P35/00 , A61P29/00 , A61M25/00
CPC分类号： A61K9/0019 , A61K38/1875 , C07K14/51
摘要： The present invention is directed to methods and compositions for systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily. According to the invention, an exemplary bioactive agent is BMP-7 The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the site of intravascular delivery of the bioactive agent.
摘要翻译： 本发明涉及用于全身递送最小可溶性生物活性剂的方法和组合物，所述生物活性剂例如但不限于TGF-和bgr的蛋白质; 超家族 根据本发明，示例性生物活性剂是BMP-7。本发明进一步提供骨骼疾病例如骨质疏松症的微创全身治疗以及受损或患病的非矿化组织和器官等肾脏的微创全身治疗。 本发明的实践消除了生物活性剂血管内递送部位的不良副作用。
-
-
搜索结果
3 条记录 (耗时 0.02 秒)
